



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/763,462	05/01/2001	Jehad Charo	1430-264	7394

23117 7590 08/24/2005

NIXON & VANDERHYE, PC  
901 NORTH GLEBE ROAD, 11TH FLOOR  
ARLINGTON, VA 22203

EXAMINER
----------

KATCHEVES, KONSTANTINA T

ART UNIT	PAPER NUMBER
----------	--------------

1636

DATE MAILED: 08/24/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

**Notice of Allowability**  
*Supplemental*

Application No.

09/763,462

Examiner

Konstantina Katcheves

Applicant(s)

CHARO ET AL.

Art Unit

1636

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to 3/18/2005.
2. ☒ The allowed claim(s) is/are 1-13,24-28 and 33-47.
3. ☒ The drawings filed on 23 February 2001 are accepted by the Examiner.
4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
  - a) ☐ All b) ☐ Some\* c) ☐ None of the:
    1. ☐ Certified copies of the priority documents have been received.
    2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
    3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).
  - \* Certified copies not received: \_\_\_\_\_.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.  
**THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.**

5. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
6. ☐ CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.
  - (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached
    - 1) ☐ hereto or 2) ☐ to Paper No./Mail Date \_\_\_\_\_.
  - (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date \_\_\_\_\_.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
7. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

**Attachment(s)**

- |   |  |
|---|--|
| 1. <input type="checkbox"/> Notice of References Cited (PTO-892)  | 5. <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)            |
| 2. <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                                | 6. <input type="checkbox"/> Interview Summary (PTO-413),<br>Paper No./Mail Date _____. |
| 3. <input type="checkbox"/> Information Disclosure Statements (PTO-1449 or PTO/SB/08),<br>Paper No./Mail Date _____ | 7. <input checked="" type="checkbox"/> Examiner's Amendment/Comment                    |
| 4. <input type="checkbox"/> Examiner's Comment Regarding Requirement for Deposit<br>of Biological Material          | 8. <input type="checkbox"/> Examiner's Statement of Reasons for Allowance              |
|   | 9. <input type="checkbox"/> Other _____.   |

### EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Gary Tanigawa on 17 August 2005.

The application has been amended as follows:

24. A combination of components for separate, sequential or concomitant administration in a method of vaccinating a mammal against a disease state, comprising administering to said mammal a combination comprising a nucleotide sequence encoding for, within an appropriate vector, an antigenic peptide associated with the disease state and not associated with a virus particle, and a Schiff base forming compound which enhances both humoral and cellular immune responses initiated by the antigenic peptide, the compound being selected from the group consisting of:

4-(2-formyl-3-hydroxyphenoxy)methyl)benzoic acid;

5-(2-formyl-3-hydroxyphenoxy)pentanamide;

*N,N*-diethyl 5-(2-formyl-3-hydroxyphenoxy)pentanamide;

*N*-isopropyl 5-(2-formyl-3-hydroxyphenoxy)pentanamide;

ethyl 5-(2-formyl-3-hydroxyphenoxy)pentanoate;

5-(2-formyl-3-hydroxyphenoxy)pentanonitrile;

Art Unit: 1636

(±)-5-(2-formyl-3-hydroxyphenoxy)-2-methylpentanoic acid;  
5-(2-formyl-3-hydroxyphenoxy)-2,2-dimethylpentanoic acid;  
methyl 3-(2-formyl-3-hydroxyphenoxy)methylbenzoate;  
3-(2-formyl-3-hydroxyphenoxy)methylbenzoic acid;  
benzyl 5-(2-formyl-3-hydroxyphenoxy)pentanoate;  
5-[4-(2-formyl-3-hydroxyphenoxy)-*N*-butyl]tetrazole;  
7-(2-formyl-3-hydroxyphenoxy)heptanoic acid;  
5-(2-formyl-3-hydroxy-4-*n*-propoxyphenoxy)pentanoic acid;  
5-(4,6-dichloro-2-formyl-3-hydroxyphenoxy)pentanoic acid;  
5-(2-formyl-3-hydroxyphenoxy)-*N*-methylsulfonylpentanamide;  
ethyl 4-(2-formyl-3-hydroxyphenoxy)methylbenzoate;  
5-(4-chloro-2-formyl-3-hydroxyphenoxy)pentanoic acid;  
5-(3-acetylamino-2-formyl phenoxy)pentanoic acid;  
Aminoguanidine;  
4-(2-formyl-3-hydroxyphenoxy)butanoic acid;  
6-(2-formyl-3-hydroxyphenoxy)hexanoic acid;  
ethyl 4-(3-acetylamino-2-formylphenoxy)methylbenzoate;  
4-(3-acetylamino-2-formylphenoxy)methylbenzoic acid;  
2-(2-formyl-3-hydroxyphenoxy)methylbenzoic acid;  
5-[4-(2-formyl-3-hydroxyphenoxy)methyl]phenyl]tetrazole;  
5-(2-formyl-3-hydroxy-4-methoxyphenoxy)pentanoic acid;  
3-(2-formyl-3-hydroxyphenoxy)propionitrile;

Art Unit: 1636

4-Hydroxyphenylacetaldehyde;

Phenylacetaldehyde;

4-Methoxyphenylacetaldehyde;

1-hydroxy-2-phenylpropane;

3-Phenylpropanal;

4-Nitrobenzaldehyde;

Methyl 4-formylbenzoate;

4-Chlorobenzaldehyde;

4-Methoxybenzaldehyde;

4-Methylbenzaldehyde;

8,10-Dioxoundecanoic acid;

4,6-Dioxoheptanoic acid;

Pentanedione;

5-methoxy-1-tetralone;

6-methoxy-1-tetralone;

7-methoxy-1-tetralone;

2-tetralone;

3-hydroxy-1-(4-methoxyphenyl)-3-methyl-2-butanone;

2',4'-dihydroxy-2-(4-methoxyphenyl)acetophenone;

2-hydroxy-1-(4-methoxyphenyl)-pent-2-en-4-one;

Naringenin 4',5,6-trihydroxyflavone;

4'-methoxy-2-(4-methoxyphenyl)acetophenone;

Art Unit: 1636

6,7-dihydroxycoumarin;

7-methoxy-2-tetralone;

6,7-dimethoxy-2-tetralone;

6-hydroxy-4-methylcoumarin;

Homogentisic acid gamma lactone;

6-hydroxy-1,2-naphthoquinone;

8-methoxy-2-tetralone;

and physiologically acceptable salts thereof, where appropriate.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Konstantina Katcheves whose telephone number is (571) 272-0768. The examiner can normally be reached on Monday, Tuesday, Thursday and Friday 7:30 to 5:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Remy Yucel, Ph.D. can be reached on (571) 272-0781. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.



JAMES KETTER  
PRIMARY EXAMINER

Art Unit: 1636

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Konstantina Katcheves  
Examiner  
Art Unit 1636